Femasys Inc. is a biomedical innovator that develops and commercializes therapeutic and diagnostic products for women's health. The company focuses on infertility treatment and permanent birth control solutions. Its product portfolio includes devices such as FemaSeed for intrauterine insemination, FemVue for tubal assessment, FemSperm for sperm handling, FemBloc for non surgical permanent contraception, FemChec for confirming tubal occlusion, and FemCerv for cervical cancer sampling.

Femasys generates revenue primarily from the sale of its medical devices to healthcare providers such as gynecologists, reproductive endocrinologists, and infertility clinics. The company sells products directly through its own sales force and also works with distribution partners in select international markets. Revenue streams include the infertility product line comprising FemaSeed, FemVue and FemSperm, and the permanent birth control line comprising FemBloc and its companion diagnostic FemChec, as well as the cervical cancer product FemCerv.

Femasys occupies a niche position in the women's health market by offering alternatives to established procedures such as surgical tubal ligation, intrauterine insemination and in vitro fertilization. Its competitive advantages stem from a first of its kind non surgical permanent birth control technology, a deep patent portfolio with over two hundred issued patents globally, and the ability to conduct procedures in a physician's office without general anesthesia. The company faces competition from established device manufacturers in the intrauterine insemination space, from fertility clinics offering IVF, and from providers of traditional tubal ligation, but differentiates itself through lower procedural risk, reduced cost and office based delivery.

Femasys serves gynecologists, reproductive endocrinologists, infertility specialists and other women's health practitioners who perform office based procedures. The company has announced collaborations with prominent infertility centers including Boston IVF, HRC Fertility and CNY Fertility, and has secured distribution partners in Spain and the France/Benelux region for its products. Its customers are primarily located in North America, with expanding presence in Europe and other international markets.